SOURCE: Advitech Inc.

June 06, 2005 09:00 ET

Echoes Financial Network Inc. to Provide Investor Relations Services to Advitech With

QUEBEC -- (MARKET WIRE) -- June 6, 2005 -- Advitech Inc. ("Advitech" or "the Company") (TSX-V: AVI), a Canadian biotech company involved in the development of a new oral treatment for psoriasis, today announced that Echoes Financial Network Inc. ("Echoes") has agreed to contribute strategic investor relations and financial communications services to the Company.

Echoes, a financial media relations firm with offices in Montreal and New York, should provide Advitech with an increased awareness from the Canadian and U.S. financial communities. Echoes will be in charge of promoting the Company with financial analysts through its platform (, as well as of organizing meetings and presentations to financial agents with an interest in the biotech sector.

"We are very pleased to be associated with Echoes to expand the number of investors interested in our company. We are confident that it will lead to increased visibility that will be beneficial for our shareholders," stated Advitech CFO Michel Lamontagne. "With major clinical trial results for our psoriasis oral treatment on the verge of being released, our company will begin a momentous phase of its development, and we believe that it is extremely important to arrange for much broader distribution of our information throughout the financial industry," CFO Lamontagne added.

Advitech will pay Echoes a monthly retainer fee of $2,500 for professional services. The initial contract term is for six months. Neither Echoes nor any of its principals has an ownership interest, whether directly or indirectly, in Advitech or its securities, and the Company has not granted Echoes or its principals any right to acquire such an interest. The principals of Echoes are: Dominic Sicotte, President, and Martin Lavoie, Senior Vice-President.

About Advitech

Advitech is a biotechnology company specializing in the development of bioactive ingredients from dairy proteins. Its key focus areas are in the fields of immunology and inflammation. Its main platform, XP-828L, is a growth factor complex used as an oral product for mild to moderate psoriasis and also for other immune-mediated chronic inflammatory diseases. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • For further information, please contact:

    Advitech Inc.
    Michel Lamontagne, MBA
    Vice-President and Chief Financial Officer
    (418) 686-7498, ext. 237

    Echoes Financial Network Inc.
    Dominic Sicotte, (514) 842-9551, ext. 236
    Martin Lavoie, (514) 842-9551, ext. 231